By Lisa Kerner
Erie, Pa., Jan. 20 - Telomolecular Corp. said it will use a private placement of $3 million to develop commercial products that repair degraded chromosomal telomeres in living animals.
Repairing degraded telomeres in vivo may correct a variety of devastating and presently incurable age-related diseases such as macular degeneration, atherosclerosis, arteriosclerosis, liver cirrhosis, and other degenerative disorders caused by telomere shortening.
Telomere therapy based on Telomolecular nanotechnologies represents the first practical step in rejuvenating human beings and extending their lifespans, according to a company news release.
In March 2007, the company plans to release a line of cosmetic products designed to rejuvenate skin and fibroblast tissues.
Telomolecular also plans a future release of general and targeted pharmaceutical products useful in the treatment of aging and age-related disease, after receiving Food and Drug Administration approval. The company intends to "make young again" a living sheep in October of 2006 by delivering proteins such as telomerase reverse transcriptase in vivo with a new FDA-approved protein delivery technology.
"In respect to significant technological advances, the world often expects due delay, however, we feel that working products capable of significantly reversing the process of human aging, in safe ways, will soon make an impact on international financial markets," said Telomolecular chief executive officer Matthew A. Sarad in the release. "The corporation is targeting outside investors that might also make good industry partners such as Amgen, Aastrom Biosciences, ICOS Corporation, Geron Corp. and other such entities."
Telomolecular Corp.'s purpose is engineer a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. The company is based in Sacramento, Calif.
| Issuer: | Telomolecular Corp.
|
| Issue: | Private placement
|
| Amount: | $3 million
|
| Announcement date: | Jan. 20
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
